Nirsevimab prevents RSV-associated lower respiratory tract infections in preterm infants Aug. 14, 2020 No Comments
Notable responses seen in COVID-19 patients with respiratory failure given RLF-100 Aug. 13, 2020 No Comments
AnaptysBio reports interim analysis data from ECLIPSE phase II study of etokimab Aug. 11, 2020 No Comments
EC approves Xolair as treatment of severe chronic rhinosinusitis with nasal polyps Aug. 7, 2020 No Comments
Redx snags potential $377M deal with Astrazeneca for fibrosis-targeting RXC-006 Aug. 4, 2020 By Nuala Moran No Comments LONDON – Redx Pharma plc is in the process of handing its RXC-006 program over to Astrazeneca plc, after signing a potential $377 million development and commercialization deal for the porcupine inhibitor in the treatment of fibrotic disease.Read More
RSS